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Background: Autologous arteriovenous fistulae (AVF) are the optimal form of vascular access for haemodialysis.
AVFs typically require 6 to 8 weeks to “mature” from the time of surgery before they can be cannulated. Patients
with end-stage renal disease needing urgent vascular access therefore traditionally require insertion of a tunnelled
central venous catheter (TCVC). TCVCs are associated with high infection rates and central venous stenosis.
Early cannulation synthetic arteriovenous grafts (ecAVG) provide a novel alternative to TCVCs, permitting rapid access to
the bloodstream and immediate needling for haemodialysis. Published rates of infection in small series are low.
The aim of this study is to compare whether TCVC ± AVF or ecAVG ± AVF provide a better strategy for managing patients
requiring immediate vascular access for haemodialysis.
Methods/design: This is a prospective randomised controlled trial comparing the strategy of TCVC ± AVF to ecAVG ± AVF.
Patients requiring urgent vascular access will receive a study information sheet and written consent will be
obtained. Patients will be randomised to receive either: (i) TCVC (and native AVF if this is anatomically possible) or
(ii) ecAVG (± AVF).
118 patients will be recruited. The primary outcome is systemic bacteraemia at 6 months. Secondary outcomes
include culture-proven bacteraemia rates at 1 year and 2 years; primary and secondary patency rates at 3, 6, 12 and
24 months; stenoses; re-intervention rates; re-admission rate; mortality and quality of life. Additionally, treatment delays,
impact on service provision and cost-effectiveness will be evaluated.
Discussion: This is the first randomised controlled trial comparing TCVC to ecAVG for patients requiring urgent vascular
access for haemodialysis. The complications of TCVC are considered an unfortunate necessity in patients requiring
urgent haemodialysis who do not have autologous vascular access. If this study demonstrates that ecAVGs provide a
safe and practical alternative to TCVC, this could instigate a paradigm shift in nephrology thinking and access planning.
Trial registration: This study has been approved by the West of Scotland Research Ethics Committee 4 (reference no.
13/WS/0087, 28 August 2013) and is registered with the International Standard Randomised Controlled Trial Number
Register (reference no. ISRCTN80588541, 27 May 2014).
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Vascular access dysfunction is the leading cause of mor-
bidity amongst patients with end-stage renal disease
(ESRD) and is a key performance indicator for haemodi-
alysis service provision [1]. Complications of vascular ac-
cess are responsible for over 20% of all hospitalisations
in patients on haemodialysis and account for one-third
of all inpatient renal bed use [2].
Autologous arteriovenous fistulae (AVFs) are the vas-
cular access modality of choice [1,3] with fewer infective
and thrombotic complications than the alternatives [1,4]:
tunnelled central venous catheters (TCVCs) and pros-
thetic arteriovenous grafts (AVGs). The major limita-
tions to native AVF usage are a 6 to 8 week
“maturation” lag from creation to first cannulation and
30 to 50% early failure rate [5,6]. Unfortunately, due to a
combination of late referral, primary access failure and
acute presentation of renal failure, 40 to 50% of incident
patients do not have a functioning AVF when they com-
mence dialysis [3,7,8]. Given the unpredictable progres-
sion of decline in renal function to ESRD [9,10] and the
fact that 30 to 35% of patients needing to start haemodi-
alysis are “crashlanders” (known to the renal services for
<90 days) [3], whilst desirable, it is not always practic-
ably possible to achieve autologous vascular access for
all patients prior to commencing haemodialysis. Current
practice necessitates TCVC for these patients until de-
finitive vascular access can be secured. Patients who
began haemodialysis via a TCVC are more likely to re-
main with TCVC [11]; therefore, optimizing incident
vascular access is vitally important.
TCVCs are associated with a significantly higher risk
of infection, mortality, mechanical complications and
other chronic problems such as immunosuppression,
malnutrition and central venous stenosis than other
forms of vascular access [1,12]. A recent Scottish study of
2,666 patients revealed a two- to threefold increased risk in
mortality (all-cause mortality, cardiovascular or infection-
related mortality) and a sevenfold increase in death from
septicaemia with the use of TCVCs [12]. For these reasons,
TCVC are considered an option of last resort.
AVGs provide an intermediate option between AVF
and TCVCs, permitting earlier cannulation than AVF
but lower bacteraemia rates than TCVC (0.6 per 1,000
dialysis days) [13]. The longevity and patency of AVGs
are variable and almost certainly poorer than native AVF
with 1-year primary patency rates ranging from 40 to
60% [14]. However, with aggressive re-intervention for
the management of thrombosis, secondary patency rates
of as high as 90% at 1 year can be achieved [15].
Traditional AVGs still require a delay of approximately
2 weeks from implantation to initial cannulation, com-
pelling TCVC insertion as a stop-gap measure in the ma-
jority of cases. However, early cannulation arteriovenousgrafts (ecAVGs), which permit immediate needling, may
provide a novel alternative permitting TCVC avoidance in
many cases [16]. The GORE® Acuseal™ (W.L.Gore
Associates Ltd., Flagstaff, Arizona) vascular access graft is
one such ecAVG. It is a tri-layer graft with unique sealing
properties to permit safe cannulation within 24 hours of
insertion. The tri-layer construction comprises an inner
layer of heparinised expanded polytetrafluoroethylene, an
outer layer of standard expanded polytetrafluoroethylene
graft, and a central elastomeric layer [17]. This central
layer gives the graft its unique “low bleed” properties and
permits early cannulation, reducing the time to achieve
haemostasis significantly compared to standard expanded
polytetrafluoroethylene.
These unique properties of Acuseal™ and other
ecAVGs make them an attractive alternative to TCVCs
in patients requiring urgent vascular access for haemodi-
alysis with theoretical benefits of reduced infection and
avoidance of long-term TCVC complications such as
central venous stenosis. In small series, the Acuseal™
graft has been shown to be beneficial in patients requir-
ing urgent access for haemodialysis as a “bridge” to AVF
maturation or transplantation, as well as in patients with
pre-existing occlusion of their central veins [18]. A re-
cent observational study conducted in our unit has indi-
cated that ecAVG provide a practical, feasible and
acceptable alternative to TCVCs in patients requiring
urgent vascular access for haemodialysis [19]. Further-
more, cost-analysis has shown that the additional initial
outlay costs of consumables can be offset against re-
duced septic complications, hospital admissions and bed
days, with potential cost savings of nearly £1,000 at
6 months with ecAVG compared to TCVCs [20].
We now intend to test this hypothesis in a rando-
mised controlled trial comparing TCVCs (± AVF) to
ecAVG (±AVF).Methods/design
Overview
This is a single centre randomised controlled trial. This
study has been approved by the West of Scotland Research
Ethics Committee 4 (reference no. 13/WS/0087) and is
registered with the International Standard Randomised
Controlled Trial Number Register (ISRCTN80588541).
This study will be performed in keeping with the require-
ments of the Declaration of Helsinki.Hypothesis
The use of ecAVGs ± AVFs will reduce the rate of
culture-proven bacteraemia at 6 months compared to
the use of TCVCs ± AVFs in patients with ESRD requir-
ing urgent vascular access for haemodialysis.
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This study aims for a strategy of comparing ecAVG± au-
tologous AVF (if anatomically suitable) to TCVC± autolo-
gous AVF in patients requiring urgent vascular access for
haemodialysis. The primary outcome measure is culture-
proven bacteraemia at 6 months. Secondary outcomes
include culture-proven bacteraemia at 12 and 24 months;
primary, secondary and functional patency rates at 3, 6, 12
and 24 months; stenosis, thrombosis and re-intervention
rates (including the need for urokinase infusions, AVG
declotting procedures and TCVC replacement); other
complications, including local infection, suspected access-
related infection, steal syndrome, cardiovascular comprom-
ise, central venous stenosis; mortality at 6, 12 and
24 months, quality of life (assessed by EQ-5D) at 6 months;
future sites of vascular access; re-admission rates and bed
day utilisation and efficiency and efficacy of dialysis (urea
reduction ratio, access flows, and recirculation). Addition-
ally delays to treatment and the impact on service
provision (access to theatre, and so forth) will be assessed
to evaluate the practicalities of each treatment regimen.
Cost-utility analysis will also be performed. Definitions of
patency and other access-related complications will be as
described by Sidawy and colleagues [21].
Study centre
The study will be conducted at the Western Infirmary,
Glasgow, UK. This university teaching hospital provides
a tertiary referral vascular access service for 650 haemo-
dialysis patients in the West of Scotland. We perform
approximately 400 vascular access procedures, including
100 complex access procedures, annually. We have a
wealth of experience using ecAVGs with published local
outcomes highlighting our current practice [18-20]. The
necessary volume of clinical cases, presence of clinical
expertise and equipment required for this study is well
established in this unit.
Patients and enrolment
All patients will be admitted under the care of the
Nephrology Team at the Western Infirmary. Patients re-
quiring urgent vascular access for haemodialysis will be
assessed by their clinical team. Temporary venous cath-
eter will be inserted to permit life-saving haemodialysis
if required. The clinical team will then refer the patient
to the Vascular Access Co-ordinator for TCVC insertion
and definitive vascular access creation.
All patients referred for TCVC insertion will be
assessed by a member of the research team within
6 hours of referral. All adult patients (≥18 years old)
with ESRD requiring urgent vascular access for
haemodialysis will be eligible to participate. Patients will
be excluded if they have significant cardiorespiratory co-
morbidities or peripheral vascular disease precludinganaesthesia or ecAVG creation, a brachial artery <2 mm
diameter on duplex ultrasound, significant and untreated
systemic sepsis with positive blood cultures, women who
are pregnant or breast-feeding, lack of capacity or ability to
provide informed consent or if they decline to participate.
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. All suitable patients will be fully
informed that they are being asked to participate in a re-
search study. The procedures involved in the study, and
the chances of being assigned randomly to one of two
groups will be explained in person and via an informa-
tion sheet approved by the West of Scotland Ethics
Committee. A signed consent form will be obtained
from each patient and retained by the investigators.
Patients will be made aware of their right to withdraw
from the study at any time without adverse effects on
their clinical care.
Pre-operative management
All patients will undergo Duplex ultrasound of both
arms. Both the venous and arterial tree will be assessed
and a pre-operative plan made to site both ecAVG and
native AVF. Wherever possible, care will be taken to pre-
serve all sites for future autologous access and the site of
native AVF will always be favoured in the non-dominant
arm and distally first. ecAVG will be placed to accom-
modate optimal AVF placement. For example, a native
left radiocephalic fistula and right forearm loop or right
brachioaxillary graft would be favoured in a left-handed
patient with good native vessels and no previous vascu-
lar access; whilst revision of an existing occluded left
brachiocephalic fistula with outflow stenosis using an
interposition ecAVG and contralateral elbow AVF would
be considered in an elderly patient with poor vessels and
occluded existing AVF.
Randomisation
A computer generated 1:1 allocation sequence will be
created by an independent operator who is not directly
involved with the study. Allocation concealment will be
achieved using sequentially numbered sealed opaque
envelopes.
Blinding
Due to the nature of the treatment and any subsequent
interventions, it is not possible to blind either patient,
surgeon or investigator to the treatment allocation.
Treatment strategies
Patients will be randomized to receive either ecAVG±AVF
or TCVC±AVF.
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TCVC ±AVF reflects standard practice at our institu-
tion. Patients randomized to receive TCVC ±AVF will
be referred to the Interventional Radiology Department
for TCVC insertion (either by a radiologist or nurse spe-
cializing in TCVC insertion).
Tunnelled Ash Split® (Medcomp, Harleysville, PA,
USA) 14Fr double-lumen polyurethane haemodialysis
catheters will be inserted with 280- or 320-mm catheters
used for right- and left-sided cannulation, respectively.
Catheters will be inserted via a Seldinger technique
under image guidance. A standard catheter care protocol
will be employed throughout the study period. This de-
mands complete sterile precautions during catheter in-
sertion and upon manipulation of the hub. Following
catheter hub manipulation, the skin surrounding the in-
sertion site is soaked with chlorhexidine solution prior
to a sterile dressing being applied. An interdialytic lock
with heparin 5,000 iU/ml to the internal volume of the
catheter will be employed.
First haemodialysis via the TCVC will be performed by
trained nursing staff within the InPatient Renal Unit at
the Western Infirmary. A record of any difficulties or
complications with initial dialysis will be made. The tim-
ing of the first dialysis via the TCVC will be made at the
discretion of the nephrology team, as will the need for
anticoagulation. A record of these factors will be kept.
The patient will be discharged to dialyse at their
Outpatient Dialysis Unit at the discretion of the nephrol-
ogy team. Any problems that subsequently develop with
the TCVC will be referred to and managed by the neph-
rology team at the Western Infirmary as is standard
practice. These will be recorded in the patient’s elec-
tronic patient record and reported to the Principal
Investigator.
ecAVG ± AVF
Patients randomised to the ecAVG ±AVF arm of the
study will be immediately assessed by a member of the
anaesthetic team. An operative slot will be found within
either emergency or elective theatres at the Western
Infirmary for ecAVG creation within 24 hours.
All patients will be treated with pre-operative prophy-
lactic vancomycin 1 g intravenously (or teicoplanin if the
patient is vancomycin allergic). ecAVG insertion will be
performed by a single operating surgeon either under
supraclavicular block or general anaesthetic.
The patient’s skin will be prepared with alcoholic beta-
dine, draped in a standard fashion and an Ioban™ skin
covering (3 M Healthcare, Bracknell, UK) applied to
maintain strict asepsis. The vessels will be exposed and
controlled in a standard fashion. The Acuseal™ graft will
then be tunnelled in the subcutaneous fat using standard
tunnelling tools. A 4-cm longitudinal venotomy will beperformed and the graft spatulated at the venous end in
an attempt to minimize venous stenosis. The arteriot-
omy will be a standard size to accommodate the graft.
Arterial and venous anastomoses will be performed
using continuous 5.0 Prolene. Collatamp™ (Tribute
Pharmaceuticals, Milton, Ontario, Canada) will be
inserted into the wounds prior to closure to minimize
the risk of infection. Drains will be placed at the sur-
geon’s discretion.
Post-operatively the patient will be managed within
the Inpatient Renal Unit of the Western Infirmary. First
cannulation of the ecAVG will be performed by our
trained dialysis nursing staff in agreement between the
Nephrology and Surgical Teams as the patient’s clinical
condition dictates. This may be as soon as 30 minutes
post-operatively.
Sharp needles (17 G), low flows (200 to 250 ml/min)
and minimal heparin will be used for first cannulation of
ecAVGs. Full aseptic technique will be used for cannula-
tion and direct pressure applied at the needle sites for at
least 10 minutes after the needles have been removed.
These same techniques will be used for the first 2 weeks
of cannulation. Thereafter, higher flow rates may be used
if necessary to achieve adequate dialysis clearance. Suc-
cess and complications of dialysis sessions and cannula-
tion will be recorded. At least two successful
cannulations of the ecAVG will be performed prior to
discharge to the Outpatient Dialysis Unit. All patients
will continue on intravenous vancomycin for a week
post-operatively. Heparin, warfarin and anti-platelet
agents will be administered at the discretion of the operat-
ing surgeon. All patients who re-present with thrombotic
complications will be anti-coagulated with warfarin (inter-
national normalised ratio 2–3) unless contraindicated.
Should the patient develop any problems with their
ecAVG upon discharge they will be reviewed immedi-
ately by a member of the Renal Surgical Team at the
Western Infirmary as is standard practice. In the event
of thrombosis of ecAVG, aggressive attempts will be
made by both the surgical and radiological teams to sal-
vage the dialysis access as is standard practice. All com-
plications will be recorded within the patient’s electronic
case record and reported to the research team.Autologous AVF
Patients in both treatment arms will also undergo creation
of an autologous AVF (if this is anatomically possible) at
the first available opportunity. The ecAVG/TCVC will
continue to be utilized for haemodialysis until the AVF is
mature enough to cannulate. The decision to undertake
first cannulation of the AVF will be taken by the clinical
team (normally ~6 weeks after creation) and recorded
within the patient’s electronic patient record.
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AVF, the fate of an ecAVG, which is no longer required,
will be decided after discussion between the patient and
surgical team. In the majority of cases it will be left in
situ but can be removed or ligated if required/wished.
TCVCs will be removed by the surgical team after six
successful AVF cannulations as is standard practice.
Follow-up and data collection
All patients will be reviewed by the research team on day
1, day 7 and 3, 6, 12 and 24 months following insertion of
ecAVG/TCVC and 6 weeks following creation of AVF.
Additionally surveillance of ecAVG will be performed by
both ultrasound and venography at 3-monthly intervals.
Data will be collected prospectively from the operative
notes and Scottish Electronic Renal Patient Record.
Patient demographics will be obtained including age,
gender, ethnicity, weight, body mass index, dialysis sta-
tus, current access modality and co-morbidities. Details
of operative surgery, anaesthetic, site of ecAVG, TCVC
and AVF and perioperative complications will be re-
corded. Date and details of first cannulation/utilisation
of ecAVG/TCVC will be recorded in the case report
form along with the date and nature of any complica-
tions. Quality of life will be assessed at 6, 12 and
24 months. All data will be anonymised. Case report files
will be archived in a locked facility for a period of 5 years.
Criteria for discontinuation
Every effort will be made to retain patients in the trial
and to minimise withdrawals. However, any severe or
life-threatening event will be sufficient to remove a pa-
tient from the study. Data collected prior to the point of
withdrawal from the study will be retained. Patients may
request to be withdrawn from this study at any time.
Reasons for withdrawal will be documented. Intention-
to-treat analysis will be performed.
Sample size and statistical considerations
Locally, 24% of TCVCs result in systemic bacteraemia
within 6 months [19]. In order to calculate sample size,
we made the following assumptions: type 1 error (α) was
set at 0.05 and type 2 error (β) at 0.8. Therefore, if we
assume a systemic bacteraemia rate in the TCVC arm of
24% at 6 months and propose a bacteraemia rate of 5%
at 6 months in the ecAVG arm, then 53 patients are re-
quired in each group. In order to account for attrition of
around 10%, we aim to recruit 118 patients. This magni-
tude of difference between the two treatment arms is
considered to be clinically significant and realistic given
the published rates of systemic bacteraemia for ecAVG
in our institution [18].
The null hypothesis for this study is that there is no dif-
ference between systemic bacteraemia rates at 6 monthsin patients who require urgent vascular access for haemo-
dialysis treated with TCVC±AVF and those treated with
ecAVG±AVF.
Descriptive statistics will be used to describe continu-
ous variables. Results for continuous variables will be re-
ported as mean (± standard deviation) or median
(interquartile range). Assuming normal distribution, treat-
ment groups will be compared using a student’s t-test
or, if data are found to not be normally distributed, a
Mann–Whitney U-test will be used. Analysis will be
performed on an intention-to-treat basis. Additionally,
a cost-consequence analysis will be conducted, compar-
ing the costs (for example, treatment, procedures,
hospital stay, and so forth) and the consequences (for
example, health outcomes such as bacteraemia epi-
sodes, mortality, and so forth) of both treatment arms.
Based on the results of our recent observational study
[19] in which 53 eligible patients presented in a 6-month
period, it is anticipated that recruitment will take ap-
proximately 18 months. Data collection will continue for
2 years beyond the date of last recruitment, though the
primary outcome will be assessed after 6 months.Adverse event reporting and safety
All adverse events will be fully recorded in the medical re-
cords and on the study case report forms. A Data
Monitoring Committee comprising of the Chief Investigator,
trial statistician and an independent nephrologist will
convene at the mid-point of the trial to evaluate
recruitment and data collection. The Data Monitoring
Committee will monitor adverse events and make rec-
ommendations as required. An interim analysis of re-
sults will be performed at the mid-point of the trial.
All adverse events will be evaluated by the Chief
Investigator for severity, expectedness and causality. Any
serious adverse events (SAEs) will be reported to the
main Research Ethics Committee and sponsor where, in
the opinion of the Chief Investigator, the event was
related (resulted from administration of any of the
research procedures) and unexpected (not listed in the
protocol as an expected outcome). SAEs will be re-
ported using the National Research Ethics Service SAE
report form for Clinical Trials of Non-Investigational
Medical Products.
Both TCVCs and AVGs are used routinely in clinical
practice with minimal complications. The most common
risk of TCVC usage is systemic bacteraemia, quoted in the
range of 1.4 to 1.8 per 1,000 catheter days [4,12,13,22].
Most commonly, Gram-positive organisms, for example
Staphylococcus Aureus, cause catheter-related bacteremia
[23]. Otherwise, catheter replacement for dysfunction
(thrombosis and malposition) occurs in approximately 0.2
per 1,000 catheter days [23]. The well-described
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ture are very rare with image-guided TCVC insertion.
Similarly, operative complications of ecAVG, including
steal syndrome and bleeding, are rare [18]. Infection
rates are lower than TCVC (approximately 0.6 per 1,000
dialysis days in most published series). The most com-
mon infective organisms are Gram-negatives, which are
more common in lower rather than upper limb accesses
[24]. Thrombosis of ecAVG is the most common com-
plication, with approximately half of ecAVGs requiring
re-intervention during the first year [14]. With aggres-
sive management strategies for thrombosis, however, it
is possible to achieve secondary patency rates ap-
proaching 90% at 1 year [15].
Any adverse events relating to either procedure will be
recorded by the staff performing the study, and necessary
investigations, treatment or follow-up arranged thereafter.
Limitations and potential solutions
Traditionally, recruitment in trials relating to vascular
access can be difficult. In one recent large study, over
2,000 patients were screened to recruit just 225 [25].
This study had very strict inclusion criteria, which can
be difficult to achieve in a heterogeneous patient popula-
tion such as ESRD. It is not anticipated that such prob-
lems will be encountered in our study for several
reasons: firstly, this will be an inclusive study (rather
than having strict inclusion/exclusion criteria); secondly,
a local pilot study [19] has demonstrated that 79 patients
had TCVCs inserted over a 6-month period and there-
fore might be approached for inclusion in this study.
The power calculation for this study is based on a
bacteraemia rate of 24% in the TCVC arm. This rate is
higher than that described in many series, but is derived
directly from our local pilot study [19]. It may be that
these higher rates of infection relate to early post-
insertion infection rates, rather than overall bacteraemia
rates for static prevalent TCVCs.
Discussion
The purpose of this trial is to investigate the hypothesis
that, in patients requiring urgent vascular access for
haemodialysis, the 6-month culture-proven bacteraemia
rate is improved by a strategy of ecAVG ±AVF com-
pared to TCVC ± AVF as this has not yet been demon-
strated in a large randomised controlled trial.
Complications of vascular access are a leading cause of
morbidity and mortality in patients with ESRD. The
healthcare costs from a catheter-related bacteraemia
range from $6,000 to $29,000 [26]. If the proposed strat-
egy of ecAVG ±AVF is found to reduce culture-proven
bacteraemia rates, it could result in significant reduction
in healthcare costs and reduced morbidity and hospital-
isation for patients with ESRD. This could lead to aparadigm shift away from TCVC in patients requiring
urgent vascular access. Conversely if TCVC ±AVF is
found to be superior, this finding would support our
current strategy of TCVC usage in this patient cohort.
Therefore, either a positive or negative result will help in-
form future practice regarding the optimal strategy of
vascular access in patients requiring urgent haemodialysis.
Trial status
Recruiting.
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